Aethlon Medical (AEMD) AI Stock Analysis

• Market Cap: $2.94M
• Dividend Yield: N/A
• Average Volume (3M): 364.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: N/A
• EPS Growth: 78.72%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Devices
• EPS (TTM): -0.85
• Shares Outstanding: 2,598,711
• 10 Day Avg. Volume: 745,522
• 30 Day Avg. Volume: 364,989
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -3.41
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: $1.50
• Price Target Upside: -5.66% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 38 Underperform
• Price Target: ―

Aethlon Medical's overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock's outlook.

Positive Factors

Clinical Trial Progress

The first cohort of three patients in the Australian Hemopurifier cancer trial were treated without device-related serious adverse events, and the Data Safety Monitoring Board recommended advancing to the second treatment cohort.

Regulatory Approval

AEMD received formal approval from India's Central Drugs Standard Control Organization to initiate a similar oncology trial at Medanta Medicity Hospital.

Negative Factors

Commercialization Uncertainty

Capital constraints and clinical uncertainty continue to weigh on visibility, maintaining a Hold rating due to the uncertain commercialization timeline of the Hemopurifier.

Financial Performance

Aethlon reported results for 1Q FY 2026 with no revenues and a net loss of $0.85 per diluted share.

Aethlon Medical Business Overview & Revenue Model

Company Description

Aethlon Medical, Inc. (AEMD) is a biotechnology company focused on developing innovative therapies for life-threatening diseases. The company primarily operates in the healthcare sector, offering medical devices and therapeutic solutions aimed at addressing unmet medical needs, particularly in the areas of oncology and infectious diseases. Aethlon's flagship product, the Hemopurifier, is a first-in-class device designed to selectively filter and remove harmful viruses and exosomes from the bloodstream, which can contribute to disease progression and immune suppression.

How the Company Makes Money

Aethlon Medical makes money through the development and commercialization of its Hemopurifier product, targeting both therapeutic and diagnostic markets. Revenue is primarily generated from grants, research and development contracts, and potential sales or licensing of its proprietary technology. As a company focused on early-stage biotechnology, Aethlon also relies on government funding and partnerships with research institutions to support its development efforts. Key factors contributing to its earnings include the expansion of its product applications, regulatory approvals, and strategic collaborations that enhance its market reach and product development pipeline.

Aethlon Medical Financial Statement Overview

Summary

Aethlon Medical faces significant financial challenges, with no revenue growth and persistent losses. The balance sheet suggests limited financial flexibility despite low leverage. Cash flow issues exacerbate these concerns, with substantial cash outflows overshadowing financing efforts. The company needs to address its revenue generation and operational efficiency to improve its financial standing.

Income Statement

Aethlon Medical's income statement reveals significant challenges, with consistent negative gross profit and net income across both TTM and annual reports. The absence of revenue in the latest TTM indicates a severe downturn. Persistent negative EBIT and EBITDA margins highlight ongoing operational inefficiencies, with no visible improvement in revenue growth.

Balance Sheet

The balance sheet shows a moderate equity position with a relatively stable debt level. The Debt-to-Equity ratio remains low, indicating conservative leverage. However, the equity ratio suggests reliance on stockholder equity for asset financing, which could limit future growth potential. Despite a sizable cash position, the company's assets are declining, hinting at potential liquidity concerns.

Cash Flow

Cash flow analysis indicates severe cash management issues, with negative free cash flow and operating cash flow across periods. The large discrepancy between operating cash flow and net income raises concerns about the sustainability of operations. Despite positive financing cash flow, likely from equity issuance, the free cash flow remains negative, reflecting ongoing cash burn.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	172.12K	0.00	0.00	574.25K	294.17K	659.10K
Gross Profit	-1.37B	-339.56K	-359.06K	574.25K	294.17K	659.10K
EBITDA	1.27M	-13.04M	-11.85M	-11.66M	-10.30M	-7.85M
Net Income	-12.58M	-13.39M	-12.21M	-12.03M	-10.42M	-7.89M
Balance Sheet
Total Assets	5.31B	7.36M	8.25M	17.51M	19.42M	10.67M
Cash, Cash Equivalents and Short-Term Investments	3.77B	5.50M	5.44M	14.53M	17.07M	9.86M
Total Debt	573.85M	649.75K	940.32K	1.21M	729.41K	42.54K
Total Liabilities	1.88B	2.24M	2.48M	2.44M	2.43M	1.38M
Stockholders Equity	3.42B	5.12M	5.77M	15.06M	17.13M	9.43M
Cash Flow
Free Cash Flow	-1.72B	-7.65M	-10.38M	-11.45M	-10.12M	-6.82M
Operating Cash Flow	-1.72B	-7.65M	-10.13M	-10.51M	-9.77M	-6.76M
Investing Cash Flow	0.00	0.00	-250.87K	-943.11K	-349.19K	-59.88K
Financing Cash Flow	-3.01M	7.73M	1.29M	8.91M	17.37M	7.13M

Aethlon Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.59
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEMD, the sentiment is Positive. The current price of 1.59 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.36, and below the 200-day MA of 3.17, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 35.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AEMD.

Aethlon Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	65 Neutral	$13.57M	―	3.29%	―	-26.17%	―
TRIB	48 Neutral	$24.73M	―	77.20%	―	-4.02%	-6.60%
BNGO	47 Neutral	$19.33M	―	-118.26%	―	-25.02%	85.08%
Sector *	46 Neutral	C$217.46M	-0.36	-24.12%	3.15%	19.33%	-0.50%
MYNZ	41 Neutral	$8.24M	―	-809.29%	―	―	―
AEMD	38 Underperform	$2.94M	―	-207.29%	―	―	78.72%
PPBT	35 Underperform	$6.76M	―	-8.59%	―	―	91.60%

Aethlon Medical Corporate Events

Aethlon Medical Achieves Milestone in Oncology Trials

In its recent financial release, Aethlon Medical reported a significant milestone in its oncology trials in Australia, announcing the first patient treated with the Hemopurifier for solid tumors not responding to anti-PD-1 antibodies on January 29, 2025. The company has also implemented strategic cost-cutting measures, reducing operating expenses by 50% from the previous year, and made protocol amendments to accelerate trial timelines and improve patient enrollment. These developments are crucial for enhancing the company’s clinical program efficiency and potentially improving therapeutic responses in future oncology efficacy trials.